Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab...
36 KB (3,118 words) - 19:25, 29 June 2024
CSCC who are not candidates for curative surgery or curative radiation. Dostarlimab (Jemperli) – was developed by GlaxoSmithKline and was first approved...
31 KB (3,266 words) - 05:29, 20 May 2024
(eptifibatide) (Europe) Jalyn (dutasteride-tamsulosin hydrochloride) Jemperli (dostarlimab) Jesduvroq (daprodustat) Lacipil (lacidipine) Lamictal (lamotrigine)...
7 KB (628 words) - 18:58, 27 December 2023
stage II or III rectal adenocarcinoma were administered single-agent dostarlimab, an anti–PD-1 monoclonal antibody, every three weeks for six months....
145 KB (15,791 words) - 05:59, 14 July 2024
for breast and ovarian cancer. TSR-042 TSR-022 Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults...
5 KB (356 words) - 01:46, 22 December 2023
Regeneron PD-1 2018 squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer Dostarlimab Jemperli Tesaro PD-1 2021 endometrial cancer...
21 KB (2,093 words) - 18:53, 25 January 2024
mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin...
12 KB (760 words) - 03:40, 23 July 2024
approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab...
48 KB (4,843 words) - 05:09, 26 July 2024
Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab...
38 KB (4,304 words) - 10:14, 21 July 2024
lung disease Rilonacept Kiniksa Pharmaceuticals recurrent pericarditis Dostarlimab GSK mismatch repair deficient recurrent or advanced endometrial cancer...
34 KB (180 words) - 22:09, 8 April 2024
humanized Amyloid beta Y Alzheimer's disease Dorlimomab aritox F(ab')2 mouse Dostarlimab Jemperli mab humanized PCDP1 Y endometrial cancer Drozitumab mab human...
135 KB (4,054 words) - 22:35, 2 July 2024
mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin...
12 KB (758 words) - 23:46, 14 March 2024
hormone replacement therapy after treatment for endometrial cancer. Dostarlimab has been approved by the FDA for therapy of endometrial cancer with specific...
105 KB (10,821 words) - 02:34, 12 July 2024
Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab L01FF09 Tislelizumab L01FF10 Retifanlimab L01FF11...
12 KB (877 words) - 15:36, 25 January 2024
Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab...
2 KB (87 words) - 01:28, 30 May 2023
(ETTs) are resistant to chemotherapy, but an immunotherapy drug called dostarlimab treats gestational trophoblastic neoplasia. ETT is a form of GTN. Stage...
3 KB (243 words) - 15:24, 29 October 2023